NCT05569057 - A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

September 30, 2022

Primary Completion Date

June 1, 2024

Study Completion Date

March 31, 2025

Conditions

Advanced Solid TumorCutaneous T-cell Lymphoma (CTCL)

Interventions

DRUG

SIM1811-03

SIM1811-03 is a first-in-class igG-1 based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumors

Trial Locations (6)

10016

NOT_YET_RECRUITING

NYU Lagone Health, New York

10029

NOT_YET_RECRUITING

Icahn School of Medicine at Mount Sinai, New York

28078

RECRUITING

Carolina Biooncology Institute, Huntersville

48202

NOT_YET_RECRUITING

Henry Ford Health, Detroit

75230

NOT_YET_RECRUITING

Mary Crowley Cancer Research, Dallas

77030

NOT_YET_RECRUITING

The University of Texas MD Anderson Cancer Center, Houston